A fast-growing body of evidence suggests that USP30 is a highly promising drug target for PD, as its inhibition can protect dopaminergic neurons from α-synuclein-associated toxicity through increased levels of mitophagy11,17,24. Here, USP30 is linked to Parkinson disease.